p53 Dysregulation in Breast Cancer: Insights on Mutations in the

Luiza Steffens Reinhardt, Kira Groen, Alexandre Xavier, Kelly A Avery-Kiejda

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

1.6field-weighted citation impact, top 14% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

Biology of p53 protein isoforms and their significance in hematological malignancies.Frontiers in oncology · 2026
Review
Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.Cell death & disease · 2024
Review
It is not all about the alpha: elevated expression of p53β variants is associated with lower probability of survival in a retrospective melanoma cohort.Cancer cell international · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Luiza Steffens ReinhardtSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0003-4443-2596

Kira GroenSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0001-9819-5982

Alexandre XavierSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0002-6397-051X

Kelly A Avery-KiejdaSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW 2308, Australia.ORCID 0000-0003-2285-9118

Hunter Medical Research Institute · AU

Funding

Cancer Institute of New South Wales CDF181205

6 · The paper itself

Abstract

In breast cancer, p53 expression levels are better predictors of outcome and chemotherapy response than

Indexed as

Breast NeoplasmsTumor Suppressor Protein p53FemaleHumansMutationMutation, MissenseProtein IsoformsProtein IsoformsTP53 protein, humanTumor Suppressor Protein p53breast cancerimmunohistochemistrynext-generation sequencingp53 isoformTP53

Identifiers

PMID37373225

DOI10.3390/ijms241210078

PMCPMC10298268

OpenAlexW4380681317

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.